Compugen Ltd. (CGEN)

Market Cap	128.04M
Revenue (ttm)	59.85M
Net Income (ttm)	1.60M
Shares Out	89.54M
EPS (ttm)	0.02
PE Ratio	79.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	227,984
Open	1.440
Previous Close	1.440
Day's Range	1.405 - 1.490
52-Week Range	0.620 - 3.030
Beta	2.65
Analysts	Strong Buy
Price Target	4.00 (+179.72%)
Earnings Date	Nov 12, 2024

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2000
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEN
• Website: https://cgen.com

Financial Performance

In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 179.72% from the latest price.

Price Target

$4.0

(179.72% upside)

Analyst Consensus: Strong Buy